Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 1615-1618, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Skopp, G.
Right arrow Articles by Aderjan, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Skopp, G.
Right arrow Articles by Aderjan, R.
Related Collections
Right arrow Drug Monitoring and Toxicology
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2002;48:1615-1618.)
© 2002 American Association for Clinical Chemistry, Inc.

Technical Briefs

Short-Term Stability of Lysergic Acid Diethylamide (LSD), N-Desmethyl-LSD, and 2-Oxo-3-hydroxy-LSD in Urine, Assessed by Liquid Chromatography–Tandem Mass Spectrometry

Gisela Skopp1a, Lucia Pötsch2, Rainer Mattern1 and Rolf Aderjan1

1 Institut für Rechtsmedizin und Verkehrsmedizin der Universität Heidelberg, Vossstrasse 2, D-69115 Heidelberg, Germany;
2 Institut für Rechtsmedizin der Universität Mainz, Am Pulverturm 3, D-55131 Mainz, Germany

aaddress correspondence to this author at: Institute of Legal Medicine, Vossstrasse 2, 69115 Heidelberg, Germany; fax 49-6221-565252, e-mail gisela_skopp@med.uni-heidelberg.de

The first 300 words of the full text of this article appear below.

Lysergic acid diethylamide (LSD) is one of the most potent hallucinogenic agents known. Recently, data on emergency department episodes related to the use of drugs commonly thought as "club drugs" have also included LSD (1). Confirmation of LSD use by testing biological fluids is still an analytical challenge because of its extensive, rapid metabolism and its instability (2)(3)(4). After ingestion of a typical street dose (40–120 µg), the concentration of LSD in urine falls to <1 µg/L within a few hours (2)(5)(6). Recently, N-desmethyl-LSD (nor-LSD) and 2-oxo-3-hydroxy-LSD (O-H-LSD) have been identified as LSD metabolites in human urine (7)(8). Measured nor-LSD concentrations were reported to be in the same concentration range as LSD, whereas the measured concentrations of O-H-LSD were severalfold higher (0.02–21.4 µg/L) (7)(9)(10)(11). The application of liquid chromatography–tandem mass spectrometry (LC-MS/MS) improved the detection of LSD use (9)(10)(12)(13)(14)(15); the method is also less susceptible to interferences when used for drug screening (16)(17). In a few studies, O-H-LSD and nor-LSD have also been measured (6)(7)(8)(10)(12)(13)(14)(15). LSD has been shown to rapidly decompose in urine samples exposed to an increased temperature or to sunlight or ultraviolet light (18)(19)(20)(21), but stability data on major LSD metabolites are not yet available.

This study was undertaken to determine the stability of LSD, O-H-LSD, and nor-LSD in urine under different storage conditions by LC-MS/MS. Data on the reaction order type and major influencing factors may be useful in . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.